By
Trending Posts
Is Eli Lilly’s Reported $2 Billion Pursuit of…
Key Highlights A Premium Bet on Psychedelic Innovation Eli Lilly is negotiating a takeover of AtaiBeckley at a…
Can Aspira Women’s Health and Cleveland Clinic’s New…
Key Highlights A Strategic Alliance Built for Scale Aspira Women’s Health and Cleveland Clinic have entered a comprehensive…
Will Big Pharma’s Billion-Dollar AI Investments Reshape the…
Key Highlights The AI Investment Race Has Officially Begun Artificial intelligence has rapidly evolved from an experimental technology…
Can Bristol Myers Squibb’s Enterprise-Wide Rollout of Anthropic’s…
Key Highlights From AI Investment to Business Value Creation Bristol Myers Squibb’s enterprise-wide adoption of Anthropic’s Claude represents…
Can Edison Scientific and Population Health Partners’ AI…
Key Highlights The Deal at a Glance Announced on June 29, 2026, the partnership pairs PHP’s proven track…
Can a $2.5 Billion AI Alliance Between Insilico…
Key Highlights The Deal at a Glance Announced at the BIO 2026 International Convention, the collaboration grants Insilico…
Can Sanofi SA’s New AI-Enabled Innovation Hub in…
Key Highlights: AI-Integrated Innovation Hubs Redefine Global R&D ModelsSanofi SA’s launch of its innovation and operations centre in…
Can Sanofi SA’s $1.2 Billion AI-Driven Autoimmune Alliance…
Key Highlights: AI-Powered Biologics Platforms Accelerate Next-Gen Antibody DiscoverySanofi SA’s licensing agreement with Kali Therapeutics Inc highlights the…
Can Eli Lilly and Company’s “Triple-G” AI-Enabled Next-Gen…
Key Highlights: AI-Driven Clinical Design Unlocks Superior Metabolic OutcomesEli Lilly and Company’s late-stage trial results for retatrutide highlight…
Trending Posts
Latest Stories
Can a $10 Billion Pipeline Opportunity Help Novartis Outrun Its Entresto Patent Cliff After a $5.94 Billion Profit Beat?
Key Highlights A Landmark Quarter Reinforcing Confidence in Novartis’ Growth Trajectory Novartis’ second-quarter results send…
Approved Two Months Early, Can GSK’s Jideytro Become the Blueprint for Faster Breakthrough Therapies in NSCLC?
Key Highlights A Landmark Approval Reflecting the Strength of GSK’s Oncology Push GSK’s announcement that…
Can Insilico Medicine’s 9-Month AI Drug Discovery Record in China Rewrite the Global Timeline for Bringing New Medicines to Patients?
Key Highlights A Landmark Shift in How Fast New Medicines Can Reach Patients Insilico Medicine’s…
Can Novo Nordisk’s Lawsuit Against Eli Lilly Push the $100 Billion GLP-1 Market Toward More Transparent, Evidence-Based Advertising?
Key Highlights A Landmark Legal Moment Reinforcing Standards in Patient-Facing Advertising Novo Nordisk’s decision to…
Gallery
